Selegilinum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 24930 |
| PubChem | 26757 |
| DrugBank | DB01037 |
| Natura chemica | |
 | |
 | |
| Formula chemica | C 13H 17N |
| Massa molaris | 187.281 g/mol |
| Natura pharmacologica | |
| Codex ATC | N04BD01 (WHO) QN06AX90 (WHO) |
| Semivita biologica | 10 h (per os) 18-25 h (trans dermem) |
| Metaboliti | N-Desmethyl- selegilinm L-amphetaminum L-methamphetaminum |
| Excretio | renibus |
| Ad usum therapeuticum | |
| Applicatio | per os |
| MedlinePlus | a667046 (Anglice) |
Selegilinum est medicamentum pharmaceuticum et inhibitor monoaminorum oxidasis B irreversibilis. Substantia in morbo Parkinson tractando et maturo et in cursibus progressivis adhibeatur.
Natura Selegilini
[recensere | fontem recensere]Natura chemica
[recensere | fontem recensere]Nomen suum est (R)-N-methyl-1-phenyl-N-prop-2-inyl-propanum-2-aminum. Massa molaris sua 187.281 g/mol.
Natura pharmacologica
[recensere | fontem recensere]Selegilinum est MAO-B inhibitor irreversibilis et medicamentum therapia morbi Parkinson[1] et maturi et progressivi.
Notae
[recensere | fontem recensere]- ↑ Ives N. J., Stowe R. L., Marro J., Counsell C., Macleod A., Clarke C. E., Gray R., Wheatley K. (Sep 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients". BMJ 329 (7466): 593